Contra Applied Genetic
13F holders, Q2 2026 (June 30)1holders
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q2 2026, 1 institutions reported holding Contra Applied Genetic in their 13F filings, unchanged from Q3 2025. 1 opened new positions and 0 sold out. The largest holder was Vermillion Wealth Management, Inc. ($0).
- Company
- Contra Applied Genetic
- CUSIP
- 038CVR015
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q2 2026: 300 shares bought, net +300 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Vermillion Wealth Management, Inc. | 0.00% | New | 300 | $0 |
"% of holder's portfolio" is CONTRA APPLIED GENETIC's weight in each manager's 13F, not the share of Contra Applied Genetic the manager owns.